Scientists from the Karolinska Institute have found two different types of cells that give rise to the fibroblasts that form fibrotic scars after spinal cord injury (SCI) depending on their location. In a study in mice, the researchers observed that pericytes acted in lesions that affect the gray matter and perivascular fibroblasts acted in the white matter. Read More
SA-012 is an N-acetylgalactosamine (GalNAc) conjugated silencing RNA (siRNA) that targets the mRNA of the PD-L1 gene and is being developed by Suzhou Siran Biotechnology Co. Ltd. for the treatment of chronic hepatitis B (CHB). Read More
Syntis Bio Inc. has announced its launch, with a focus on advancing a pipeline of oral therapies engineered for optimization in the small intestine and a portfolio of enzyme replacement therapies to treat orphan metabolic and broad digestive disorders. Read More
Bright Peak Therapeutics Inc. has raised $90 million in a series C financing. Proceeds will be used to accelerate a pipeline of next-generation immunotherapies and advance BPT-567 into a phase I/IIa trial. Read More
Schrodinger Inc. and Takeda Pharmaceutical Co. Ltd. have identified 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome. Read More
Researchers from Alteogen Inc. and affiliated organizations presented preclinical characterization of a novel long-acting growth hormone receptor (GHR) antagonist, ALT-B5. Read More
Philochem AG has discovered an ultra-high-affinity ACP3 ligand – OncoACP3 – isolated through the screening of DNA-encoded chemical libraries for the potential treatment of prostate cancer. Read More
Humanwell Healthcare (Group) Co. Ltd. has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain. Read More
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer. Read More
Hudson Therapeutics Inc., a U.S. subsidiary of Shaperon Inc., has announced the signing of a memorandum of understanding (MOU) between Shaperon and Dong-A ST Co. Ltd. for the development of nanobody-based new drugs. Read More
Nippon Shinyaku Co. Ltd. has patented discoidin domain-containing receptor 1 (DDR1) inhibitors reported to be useful for the treatment of cancer, diabetic nephropathy, hepatic and pulmonary fibrosis, myelofibrosis, nephritis, osteoarthritis and chronic renal failure. Read More
Haisco Pharmaceutical Group Co. Ltd. has presented hydroxyacid oxidase 1 (HAOX1; HAO1) inhibitors reported to be useful or the treatment of primary hyperoxaluria type 1 and kidney stones. Read More
It is known that >70% of the genes involved in pathogenic hearing loss are involved in autosomal recessive nonsyndromic hearing loss (ARNSHL), which accounts for 1 case for every 166 individuals in Iran due to the high rate of consanguineous marriage in the country. Read More
